



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Baker, MJ;Yek, KQ;Stojanovski, D

Title:

Quality control at the powerhouse: mitochondrial proteostasis dysfunction and disease

Date:

2025-08-01

Citation:

Baker, M. J., Yek, K. Q. & Stojanovski, D. (2025). Quality control at the powerhouse: mitochondrial proteostasis dysfunction and disease. *Biochemical Society Transactions*, 53 (4), pp.1105-1117. <https://doi.org/10.1042/BST20253044>.

Persistent Link:

<https://hdl.handle.net/11343/362974>

License:

[CC BY](#)

Review

Quality control at the powerhouse: mitochondrial proteostasis dysfunction and disease

Megan J. Baker , Kai Qi Yek  and Diana Stojanovski 

Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, 3052, Australia

Correspondence: Diana Stojanovski (d.stojanovski@unimelb.edu.au)



Intrinsic protein quality control (QC) mechanisms are essential in maintaining mitochondrial health and function. These sophisticated molecular machineries govern protein trafficking and import, processing, folding, maturation and degradation, ensuring the organelle's health. Disruption in mitochondrial protein QC can lead to severe, multisystem disorders with variable age of onset and progression. In this review, we provide a snapshot of the intrinsic molecular protein QC machineries in mitochondria detailing their function, localisation and substrate specificity. We also highlight how dysfunction of these molecular machines contributes to mitochondrial disease. Ultimately, elucidating the consequences of proteostatic failure offers critical insights into the pathogenesis of complex mitochondrial disorders.

Introduction

Mitochondria co-ordinate a variety of cellular processes, including oxidative phosphorylation (OXPHOS), calcium homeostasis, antiviral signalling, one-carbon metabolism and iron–sulphur cluster biogenesis [1]. These functions rely on a co-ordinated balance of protein import, folding, assembly and degradation to support proteome integrity and organelle function. Robust protein quality control (QC) mechanisms not only function in the biogenesis of mitochondrial proteins but also help mitigate proteotoxic stress and prevent the accumulation of misfolded or damaged proteins. Defects in these QC pathways are linked to a spectrum of mitochondrial diseases, neurodegenerative disorders and age-related pathologies, highlighting essential functions in mitochondrial biology. The diversity and complexity of mitochondrial proteostatic mechanisms and associated diseases have been discussed in detail previously [2,3]. While broader QC dysfunction at the cellular or organellar level is highly deleterious [4,5], this brief review aims to shine the light on molecular pathways that maintain proteostasis within mitochondria and whose dysregulation is linked to mitochondrial disease (Figure 1, Table 1). We examine mitochondrial protein QC in a sequential manner, beginning with extraction at the outer membrane, followed by organellar proteases, refolding by chaperones and resolution of aggregates by an organelle-specific disaggregase.

Quality control at the outer membrane: the ATAD1 extractase

The translocase of the outer membrane (TOM) complex is the main entry gate for nuclear-encoded proteins into the mitochondria. It is imperative this translocation pore be kept clear to support mitochondrial protein import; thus, clearance of stalled proteins at TOM is a critical aspect of protein QC. The AAA+ domain-containing ATAD1 was first described to mediate the removal of mislocalised, tail-anchored proteins from the outer mitochondrial membrane (OMM) [34]. More recently, ATAD1 has been shown to facilitate the removal of stalled precursors from TOM channels, thereby restoring import function [35] (Figure 1). Substrate extraction and translocation are powered by ATP hydrolysis through the internal core of homo-hexameric ATAD1 assemblies [36]; however, the precise mechanism by which ATAD1 engages and clears clogged TOM channels is yet to be resolved. Aside from extractase activity, ATAD1 has also been proposed to mediate the recycling of excitatory glutamatergic AMPA receptors (AMPA) at synapses [37]. Accordingly, pathogenic autosomal recessive mutation of ATAD1 results in a form of hyperekplexia (HKPX4, Mendelian inheritance in man (MIM) #618011), a severe encephalopathy characterised by extreme hypertonia, respiratory failure and early-onset refractory seizures

Received: 15 February 2025

Revised: 12 July 2025

Accepted: 5 August 2025

Version of Record

Published: 26 August 2025




Figure 1: Localisation and function of disease-linked mitochondrial protein QC factors.

Nascent mitochondrial protein precursors are targeted to the outer mitochondrial membrane (OMM), intermembrane space (IMS), inner mitochondrial membrane (IMM) and matrix by specialised import machineries (green) as dictated by intrinsic targeting signals. Mitochondrial proteases and chaperones function in both the IMS and matrix to facilitate precursor processing and folding following import, or degradation where required. At the OMM, ATAD1 co-ordinates the extraction of mistargeted proteins and clears stalled precursors from translocase of the outer membrane (TOM) complexes under import stress in an ATP-dependent manner. Within the IMS, HTRA2 and the *i*-AAA complex (YME1L1 homo-hexamer) selectively degrade misfolded or damaged protein substrate, whereas the CLPB disaggregase resolves insoluble protein aggregates. In the matrix, the HSPA9 chaperone mediates ATP-dependent import of precursor proteins, and together with the HSPD1/HSPE1 chaperone complex, facilitates protein folding. N-terminal mitochondrial targeting signals (MTS) directing precursor proteins to the matrix are removed by MPP (heterodimeric PMPCA and PMPCB) and degraded by PITRM1. From here, precursors may form mature proteins or are further processed by MIPEP and/or XPNPEP3 peptidases to remove additional amino acids at the N-terminus before forming mature proteins. Finally, three ATP-dependent proteases function to degrade misfolded or damaged proteins within the matrix: *m*-AAA (AFG3L2 homo-hexamer or AFG3L2/SPG7 heterohexamer), CLPXP and LONP1. The broad functions and associated diseases of each of these QC factors are listed within Table 1, and proteins are colour-coded according to categorisation as extractase (purple), AAA+ ATP-dependent proteases (red), ATP-independent proteases and processing peptidases (orange), chaperones (light blue) and disaggregase (pink).

[6,7]. Administration of peramppanel, an AMPAR antagonist, can mitigate hypertonicity and resolve seizures within HKPX4 patients [6], supporting the role of ATAD1 in postsynaptic AMPAR clearance. QC at TOM has rapidly emerged as a focal point in mitochondrial biology, gaining significant attention in both lower and higher eukaryotes. It will be fascinating to see how our understanding of this pathway continues to evolve, not only from a mechanistic perspective but also in relation to its interplay with other mitochondrial translocases.

Mitochondrial proteases: the guardians of protein homeostasis

Mitochondria contain over 20 proteases that function in diverse pathways, including protein QC, precursor processing, mitochondrial dynamics, stress signalling, apoptosis and metabolic regulation, collectively safeguarding mitochondrial integrity. They are categorised as ATP-dependent or independent proteases, processing peptidases or oligopeptidases [38]. ATP-dependent proteases utilise ATP hydrolysis within a common AAA+ domain to power protein unfolding prior to subsequent protein degradation. Within human mitochondria, there are eight AAA+ domain-containing proteins [39], four of which function as proteases: AFG3L2/paraplegin, YME1L1, CLPP and LONP1 (Figure 1). ATP-independent proteases, such as the HTRA2 serine protease, do not utilise ATP and instead degrade accessible protein chains. Processing peptidases PMPCA/B, MIPEP and XPNPEP3 function in precursor maturation by the release of N-terminal sequences, which are degraded by the PITRM1 oligopeptidase (Figure 1). Each of these proteases are associated with mitochondrial disease (Table 1).

Table 1: Disease-linked protein QC members

Name	Localisation	Function	Disease	Ref.
Extractase				
ATAD1	OMM	Protein extraction; translocase unclogging	HKPX4 (MIM #618011)	(6,7)
ATP-dependent proteases (AAA+)				
YME1L1	IMM (IMS)	Protein degradation; morphology	OPA11 (MIM #617302)	(8)
AFG3L2/SPG7	IMM (matrix)	Protein degradation; morphology; OXPHOS maintenance	SCA28 (MIM #610246) SPAX5 (MIM #614487) OPA12 (MIM #618977) SPG7 (MIM #607259)	(9–13)
CLXP	Matrix	Protein degradation; OXPHOS maintenance; mitochondria maturation; metabolism regulation	PRLT53 (MIM #614129) EPP2 (MIM #618015)	(14,15)
LONP1	Matrix	Protein degradation; import processing; mtDNA maintenance; OXPHOS maintenance	CODAS (MIM #600373)	(16,17)
ATP-independent proteases and processing peptidases				
PMPCA/B	Matrix	Regulatory unit (A) presequence peptidase (B)	SCAR2 (MIM #213200) MMDS6 (MIM #617954)	(18–20)
MIPEP	Matrix	Presequence peptidase (intermediate)	COXP31 (MIM #617228)	(21,22)
XPNPEP3	Matrix	Presequence peptidase	NPHPL1 (MIM #613159)	(23,24)
PITRM1	Matrix	Protein degradation	SCAR30 (MIM #619405)	(25,26)
Chaperones				
HSPD1/HSP61	Matrix	Protein folding, refolding and assembly	SPG13 (MIM #605280) HLD4 (MIM #612233)	(27,28)
HSPA9	Matrix	Protein import iron-sulphur cluster (ISC) biogenesis	EVPLS (MIM #616854) SIDBA4 (MIM #182170)	(29,30)
Disaggregase				
CLPB	IMS	Protein disaggregation	MGCA7A (MIM #619835) MGCA7B (MIM #616271) SCN9 (MIM #619813)	(31–33)

Table of mitochondrial QC factors associated with mitochondrial disease, with location, general function and Mendelian inheritance in man (MIM) codes designated. Factors are largely categorised as 'extractase', 'protease', 'chaperone' or 'disaggregase', and proteases are further segmented into ATP-dependent AAA+ family members or ATP-independent proteases and processing chaperones as detailed in the text. References (Ref.) to relevant clinical studies are included. OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; IMS, intermembrane space.

Breaking down to build up: the *i*-AAA and *m*-AAA proteases

The *i*-AAA and *m*-AAA proteases are inner mitochondrial membrane (IMM)-tethered protein complexes (Figure 1) [40,41], which are essential regulators of mitochondrial morphology and respiratory efficiency but differ in orientation and substrate base; *i*-AAA faces the intermembrane space (IMS), whereas *m*-AAA faces the matrix. Six YME1L1 monomers comprise the *i*-AAA complex, while *m*-AAA assembles either as homo-hexameric AFG3L2 or as a hetero-hexameric arrangement of AFG3L2 and the homologous paraplegin protein (encoded by the *SPG7* gene) [42,43]. In co-operation with the IMM zinc metallopeptidase OMA1, yeast mitochondrial escape 1-like 1 (YME1L1) regulates mitochondrial morphology via co-ordinated processing of OPA1, an IMM-embedded GTPase, which promotes IMM fusion and maintains cristae structure [44]. Recently, YME1L1 was shown to attenuate protein import upon TOM-clogging by degrading key components of the translocase of the inner membrane (TIM23) complex, TIMM23 and TIMM17A, to alleviate further import stress [45]. Non-assembled OXPHOS subunits, including NDUFB6, MT-ND1 and COX4I1, are also degraded by YME1L1, preserving mitochondrial respiration [46]. A single homozygous missense mutation has been reported in *YME1L1*, R149W, causing a partial loss of function [8]. This mutation prevents processing of the YME1L1 mitochondrial targeting signal, leading to rapid autocatalytic degradation of YME1L1, impaired cell proliferation and increased mitochondrial fragmentation due to aberrant OPA1 processing [8]. The disease, optic atrophy-11 (OPA11, MIM #617302), results in delayed psychomotor development, optic atrophy, intellectual disability and leukoencephalopathy.

Similar to YME1L1, ATPase family gene 3-like 2 (AFG3L2) has an essential role in degrading membrane-spanning and membrane-associated OXPHOS subunits [47,48], loss of which compromises

respiratory capacity and sensitises cells to oxidative stress [12,49]. The *m*-AAA protease mediates OMA1 maturation following import, indirectly regulating OPA1 processing and mitochondrial morphology [50,51]. *m*-AAA complexes are also essential in Ca²⁺ flux regulation [52], degrading the mitochondrial calcium uniporter subunit EMRE to prevent constitutive overactivation [53]. Pathogenic mutation of *AFG3L2* or *SPG7* results in severe neurodegenerative disorders. For *AFG3L2*, these include autosomal dominant hereditary spinocerebellar ataxia type 28 (SCA28, MIM #610246) [9], autosomal recessive spastic ataxia 5 (SPAX5, MIM #614487) [10] and optic atrophy 12 (OPA12, MIM #618977) [11]. *SPG7* is linked to hereditary spastic paraplegia type 7 (SPG7, MIM #607259) [12,13]. The strong clinical similarities between these disorders and those associated with mutation of *YME1L1*, *OPA1* and *MFN2* [8,54,55] support a primary role for both *AFG3L2* and *SPG7* in mitochondrial network maintenance and morphology.

Inside the matrix: how CLPXP and LONP1 keep the powerhouse running

In contrast with the *i*-AAA and *m*-AAA proteases, the soluble matrix proteases CLPXP and LONP1 possess more unique functions and differ greatly in structural arrangement (Figure 1) [56]. The CLPXP complex consists of a double-heptameric ring of CLPP with co-axial CLPX hexamers stacked on either side of the CLPP oligomer [57,58]. Caseinolytic mitochondrial matrix peptidase proteolytic subunit (CLPP) has limited activity alone and requires association of the caseinolytic mitochondrial matrix peptidase chaperone subunit X (CLPX) ATPase to effectively process substrate [58]. Conversely, LONP1 combines protease and ATPase activities into a single hexameric complex. The N-terminal domains of LONP1 facilitate substrate recognition, gripping and translocation towards the proteolytic domains at the core of the hexamer [59–61]. CLPXP has an established role in mitoribosome maturation [62] and mediates the selective clearance of damaged complex I subunits [63], ensuring robust OXPHOS function. Interestingly, CLPX can function independently of CLPP to facilitate partial unfolding and substrate binding of 5-aminolevulinic synthase (ALAS1), a rate-limiting enzyme of haem biosynthesis [64]. This explains the unique clinical presentations of CLPX- and CLPP-associated diseases. Pathogenic mutation of *CLPX* manifests as erythropoietic porphyria type 2 (EPP2, MIM #618015), an autosomal dominant metabolic disorder of haem biosynthesis [15]. Alternatively, *CLPP* mutations are associated with Perrault syndrome type 3 (PRLTS3, MIM #614129), an autosomal recessive disorder characterised by sensorineural hearing loss and premature ovarian failure following ovarian dysgenesis, with variable neuropathies [14].

While CLPP or CLPX deletion is tolerable across cellular and *in vivo* models, deletion of *LONP1* is embryonic lethal [65–67] and is attributed to dual chaperone and protease functionality. The ATP-binding and proteolytic domains of human lon peptidase 1 (LONP1) arrange as a hexamer, but the N-terminal domains form a trimer of dimers [59–61], which facilitates substrate recognition, gripping and translocation into the hexamer core [61]. Following import, LONP1 greets nascent protein precursors and facilitates folding or selective degradation of unprocessed, misfolded and damaged proteins [68,69]. Knockdown of *LONP1* in HeLa and HEK293 cells causes potent aggregation of mtDNA maintenance proteins and mitoribosomal subunit proteins [70]. In agreement, depletion of LONP1 from human fibroblasts leads to a partial depletion of mtDNA, concomitant with mtDNA-encoded protein translation defects [71]. Homozygous and compound heterozygous mutations in *LONP1* cause CODAS syndrome (MIM #600373), characterised by cerebral, ocular, dental, auricular and skeletal anomalies [16,17]. CODAS patients present with distinct facial dysmorphisms, including broad skulls, flattened midfaces, ptosis and a grooved nasal tip, as well as short stature, scoliosis and intellectual disabilities that progress with age [16,17]. While LONP1 has a clear association with mitoribosome biogenesis, patients carrying mutations in *LONP1* display atypical pathologies uncommon to mitochondrial disease, highlighting the broader potential physiological significance of the protein.

Mitochondrial damage control: the ATP-independent HTRA2 protease

ATP-independent proteases encompass all other mitochondrial proteases and peptidases which do not consume ATP and thereby recognise and cleave exposed hydrophobic regions of nascent, unfolded or damaged proteins. While most are involved in protein maturation [72], the functions of the HTRA2 protease are more pleiotropic. Within the IMS, high temperature requirement protein A2 (HTRA2) is reported to interact with OXPHOS subunits and other QC factors [73] and is implicated in the regulation of mitochondrial morphology via interaction with OPA1 and other cristae maintenance

factors [73,74] (Figure 1). HTRA2 has been extensively characterised as a pro-apoptotic factor following apoptotic initiation and permeabilisation of the OMM [75–77]. Upon release from mitochondria under apoptotic stimuli, HTRA2 targets and degrades the X-linked inhibitor of apoptosis (XIAP), precluding interaction between XIAP and pro-apoptotic caspases, thereby initiating cell death [77,78]. Consequently, HTRA2 activity is tightly regulated; proteolytically active HTRA2 trimers are readily inactivated upon hexamerisation, which is influenced by divalent cation binding within the C-terminal regulatory domain of HTRA2 [79,80]. Pathogenic mutation of *HTRA2* manifests as 3-methylglutaconic aciduria (3-MGA-uria), type VIII (MGCA8, MIM #617248), a severe metabolic disease characterised by movement disorders, intellectual disabilities, recurrent apnoea, respiratory insufficiency, seizures, neutropenia and elevated 3-MGA-uria [81–85]. To date, MGCA8 has been reported in 13 patients across eight families, all of whom passed within the first year of life [85].

Trimming for function: the role of PMPCA/B, MIPEP and XPNPEP3 in mitochondrial protein maturation

Many nuclear-encoded mitochondrial proteins are targeted to the organelle by an N-terminal presequence of ~20–60 amino acids recognised by receptors at TOM complexes (Figure 1) [86,87]. Following translocation across the OMM, presequence-containing precursors are delivered to IMM TIM23 complexes and are either shuttled into the matrix or laterally inserted into the IMM [88,89]. N-terminal presequences are removed by specialised processing peptidases, while intermediate peptidases can further process select precursors to yield mature protein (Figure 1). Failure to remove or efficiently degrade these targeting signals impedes protein maturation and compromises mitochondrial function.

The mitochondrial processing peptidase (MPP) proteolytically removes N-terminal presequences (Figure 1). MPP is a heterodimeric complex of the catalytic peptidase mitochondrial processing subunit beta (PMPCB) and the substrate recognition and binding subunit, peptidase mitochondrial processing subunit alpha (PMPCA). Pathogenic mutation of either MPP subunit is extremely detrimental to mitochondrial import efficiency and human health. Biallelic missense mutations within *PMPCB* cause a severe neurodegenerative disorder (MMDS6, MIM #617954) characterised by significant developmental regression within the first year of life, including progressive cerebral and cerebellar atrophy, ataxia, dystonia and seizures, often followed by early death in childhood [18]. Accordingly, the introduction of disease-linked mutations within yeast *Mas1*, homologous to human *PMPCB*, results in impaired presequence processing and accumulation of matrix precursors [18]. Conversely, pathogenic mutations within the *PMPCA* regulatory subunit contribute to autosomal recessive spinocerebellar ataxia-2 (SCAR2, MIM #213200), a non-progressive neurological disorder characterised by intellectual disability, dysarthria, loss of fine motor skills and ataxic gait [19]. Mutations proximal to or within the glycine-rich substrate-binding loop of *PMPCA* confer additional phenotypes, including severe hypotonia, respiratory insufficiency and lactic acidosis [20].

Intermediate peptidases, including the mitochondrial intermediate peptidase (MIPEP) and x-prolyl aminopeptidase 3 (XPNPEP3), further process precursors following removal of N-terminal presequences by MPP. Select precursors are matured upon cleavage of an additional octapeptide segment by MIPEP [90,91], or by removal of a single amino acid residue by XPNPEP3 (Figure 1) [92]. As with MPP, it follows that dysfunction of either MIPEP or XPNPEP3 would also be highly deleterious. Pathogenic mutations within the *MIPEP* gene contribute to combined oxidative phosphorylation deficiency 31 (COXPD31, MIM #617228), characterised by left ventricular non-compaction, developmental delay, seizures and hypertonia [21]. Isolated fibroblasts from an adult patient demonstrated reduced abundance of OXPHOS complexes I, IV and V, coupled with impaired processing of the OXA1L insertase [22], implicating MIPEP functionality in OXPHOS integrity. Curiously, XPNPEP3 has been linked to nephronophthisis-like nephropathy-1 (NPHPL1, MIM #613159), an autosomal recessive cystic kidney disease characterised by early-onset renal failure with additional neurologic involvement [23,24]. Gene products associated with nephronophthisis typically function within the cilium, basal body or centrosome complex [93]. Despite its localisation, evidence suggests that XPNPEP3 can process centrosomal proteins associated with cystic kidney diseases [24], linking the pathomechanism of NPHPL1 to other ciliopathies.

Safeguarding mitochondria from peptide buildup: the PITRM1 oligopeptidase

Following MPP processing, free N-terminal targeting presequences are primarily degraded by pitrilysin metallopeptidase 1 (PITRM1), also known as the presequence protease (PreP) [94,95]. Impaired presequence degradation upon loss of PITRM1 function impairs mitochondrial respiration, reduces membrane potential and protein import efficiency and triggers the mitochondrial unfolded protein response [96]. Loss of PITRM1 activity reciprocally dampens MPP activity, suggesting that presequence cleavage and degradation are functionally coupled [96]. Pathogenic mutation of *PITRM1* is associated with autosomal recessive spinocerebellar ataxia-30 (SCAR30, MIM #619405), largely characterised by progressive spinocerebellar ataxia, cerebellar atrophy, early-onset developmental delay and psychosis [25,26]. Concurrent with mitochondrial dysfunction, loss of PITRM1 function results in an accumulation of A β deposits within mouse models [26], and human cerebral organoids lacking PITRM1 develop progressive features of Alzheimer's disease, including protein aggregate accumulation, an increase in phosphorylated tau and neuronal cell death [97]. The link between mitochondrial dysfunction and Alzheimer's disease pathogenesis is becoming increasingly more apparent and is discussed in detail in dedicated reviews [98,99].

In summary, proteases, processing peptidases and oligopeptidases comprise the bulk of the mitochondrial protein QC machinery. Together, they survey the mitochondrial protein folding environments, degrade misfolded proteins, facilitate protein biogenesis by cleaving targeting signals from incoming precursors and co-ordinate the removal of substrate under specific stimuli. These processes often co-operate with local chaperones, which support protein folding, degradation, disaggregation, sequestration and shuttling to achieve proteostatic control. Next, we discuss key mitochondrial chaperones associated with mitochondrial QC.

The molecular bodyguards: mitochondrial chaperones

Molecular chaperones work in tandem with proteases to facilitate the folding, turnover and regulation of numerous protein substrates within mitochondria. Also referred to as heat shock proteins (HSPs), molecular chaperones are broadly classified into six functional groups: small HSP (sHSP), HSP40 (DNAJ), HSP60 (chaperonin), HSP70, HSP90 and HSP100 [100]. The HSP70/HSP90 chaperone system is best studied and, in addition to stress resistance and aggregate clearance, also facilitates the trafficking of hydrophobic mitochondrial precursors to TOM [101,102]. The IMS does not contain intrinsic HSPs, though cytosolic small HSPs are reported to be imported into the compartment under proteostatic stress [103]. Conversely, the mitochondrial matrix contains robust HSP60 (HSPD1/HSPE1) and HSP70 (HSPA9) family member chaperones which facilitate protein folding and protect against proteotoxic stress [104] (Figure 1). Here, we will discuss the function and associated pathologies of matrix chaperones HSPD1/HSPE1 and HSPA9.

HSPD1/HSPE1: orchestrating protein folding inside the matrix

HSP60 chaperonins, including the HSPD1/HSPE1 complex, form barrel-like enclosed chambers which create a folding environment for slow-folding of aggregation-prone proteins [100,105]. Akin to the GroEL/GroES system of bacteria [100,105], tetradecameric heat shock protein family D member 1 (HSPD1) is co-axially capped at one or both ends by the heptameric co-chaperone heat shock protein family E member 1 (HSPE1), conformationally regulated by cyclical ATP binding and hydrolysis along HSPD1 monomers [106,107]. The HSPD1/HSPE1 complex is posited to mediate the folding of over 200 matrix and IMM-bound proteins [108], predominated by mitoribosomal subunits and mitochondrial tRNA ligases, in addition to OXPHOS subunits and TCA cycle factors [108]. Given this functional diversity, it is not surprising that total ablation of *HSPD1* is embryonic lethal in mice [109]. Expression of a dominant negative HSPD1 mutant in human cells results in a strong reduction in matrix and IMM localised proteins, with concurrent transcriptional up-regulation of the mitochondrial integrated stress response and depletion of genes involved in cholesterol synthesis [110]. Pathogenic mutation of *HSPD1* contributes to the onset of two distinct mitochondrial diseases: autosomal dominant spastic paraplegia 13 (SPG13, MIM #605280) [27,111] and autosomal recessive hypomyelinating leukodystrophy 4 (HLD4, MIM #612233) [28].

Guiding proteins into mitochondria: the HSPA9 chaperone

HSPA9 (also known as mtHSP70 or mortalin) is a multifunctional, matrix-localised mitochondrial chaperone belonging to the HSP70 chaperone family, with broad functions in protein folding, unfolding and complex assembly. Most notably, HSPA9 facilitates the ATP-dependent import of nuclear-encoded precursor proteins into the mitochondrial matrix via the TIM23 complex [88,89]. Like HSPD1/HSPE1, HSPA9 also mediates nascent protein folding within the matrix and is proposed to be both a co-chaperone and substrate of human LONP1 [112]. Intriguingly, pathogenic mutations within the N-terminal domain of *HSPA9* have been linked to EVEN-PLUS syndrome (epiphyseal, vertebral, ear, nose, plus associated findings, EVPLS, MIM #616854), resulting in similar skeletal defects to LONP1-linked CODAS syndrome with additional craniofacial and developmental abnormalities [29]. Beyond protein import, HSPA9 functions in iron-sulphur cluster (ISC) biogenesis, detaching newly formed [2Fe–2S] clusters from ISC scaffolds within the matrix [113,114]. Iron-sulphur clusters are essential cofactors that support many critical biosynthetic processes throughout the cell, including OXPHOS, TCA cycle metabolism and haem synthesis. Accordingly, depletion of HSPA9 strongly inhibits erythroid differentiation [115], and pathogenic mutation of *HSPA9* is also known to contribute to the onset of sideroblastic anaemia type 4 (SIDBA4, MIM #182170) [30].

Breaking up the clumps: the mitochondrial disaggregase, CLPB

Under prolonged cellular stress or toxic insult, excessive protein misfolding may overwhelm proteostatic machineries, resulting in protein aggregation. Protein disaggregases function to return aggregates to an appropriate folding path in an ATP-dependent manner [116]. Caseinolytic peptidase B (CLPB) of the IMS is the sole protein disaggregase of metazoan mitochondria, utilising ATP hydrolysis within conserved AAA+ domains to power substrate disentanglement through its internal dodecameric chamber [117,118] (Figure 1). CLPB interacts with and maintains the solubility of multiple IMS substrates, including HAX1, HTRA2, PARL, OPA1 and SMAC/DIABLO, as well as key OXPHOS subunits and assembly factors [119,120]. Beyond aggregate clearance, CLPB has been implicated in antiviral innate immunity in conjunction with prohibitin complexes at the IMM [121] and is strongly up-regulated in human acute myeloid leukemia patient cells, conferring resistance to venetoclax, a inhibitor of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein [122]. *CLPB* mutation is associated with the onset of 3-MGA-uria, cataracts, neurologic involvement and neutropenia, with both autosomal dominant (MGCA7A, MIM #619835) and recessive (MGCA7B, MIM #616271) inheritance modes reported [31,32]. Dominant-negative *CLPB* mutations may also result in isolated severe congenital neutropenia (SCN) (SCN9, MIM #619813) [33], which cluster within the ATP-binding pocket of CLPB [33]. These diseases phenotypically overlap with HAX1 (SCN3, MIM #610738) and HTRA2 (MGCA8, MIM #617248) deficiencies, the strong insolubility of which could feasibly contribute to CLPB disease.

Conclusion

As mitochondrial protein QC supports proteome integrity, it follows that failure of any component may manifest in complex, multisystem pathologies. In some cases, including CLPX or HSPA9 deficiency, we can directly posit disease pathomechanisms from aberrant biological operations. Others, such as CLPB deficiency, appear to be the cumulative product of downstream substrate dysfunction. Heterogeneity in mitochondrial diseases linked to defective QC arises from the complexity and compartmentalisation of the mitochondrial proteome, the diversity of QC systems and tissue-specific metabolic demands. Disruption of any of the organellar QC systems can affect protein folding, import and degradation in distinct ways depending on the specific factor involved, the nature of the defect and the cellular context. This contributes to a wide clinical spectrum, from isolated organ dysfunction to multisystem disorders. The continuous advancement of techniques such as proteomics, CRISPR-based genome editing and cryo-electron microscopy will continue to assist us in exploring protein homeostasis mechanisms and associated disease pathologies. These protein characterisation efforts are essential not only for our own understanding of complex biochemical functions, but will also support robust diagnostic efforts and targeted therapeutic approaches in the future.

Perspectives

- Mitochondrial proteostasis is fundamental to maintaining organelle function and health, and its disruption is recognised as a driver of mitochondrial diseases, heterogeneous, multisystem disorders that vary widely in age of onset, severity and life expectancy.
- Current thinking centres on the idea that mitochondrial proteostasis is governed by co-ordinated networks of chaperones, proteases and quality control systems within and outside the organelle. These include the mitochondrial unfolded protein response, mitophagy and cytosolic surveillance mechanisms that monitor mitochondrial precursor proteins. There is growing appreciation of how import stress, misfolded or mistargeted proteins and impaired protease activity drive pathogenic cascades in disease. Furthermore, the idea that mitochondrial dysfunction can propagate stress signals to the nucleus and cytosol, altering global proteostasis, is shifting the view of mitochondria from isolated powerhouses to central hubs of cellular stress signalling.
- Future research will focus on deepening our mechanistic understanding of mitochondrial proteostasis through advanced tools such as quantitative proteomics, structural biology and high-resolution imaging. A key emerging area is the study of how mitochondria communicate proteotoxic stress to other compartments, particularly the cytosol and nucleus, and how these cross-compartment responses shape cellular fate. At the translational level, there is growing interest in targeting mitochondrial proteostasis pathways therapeutically, either by enhancing the fidelity of protein import, boosting the activity of chaperones and proteases, or modulating stress response pathways like the mitochondrial unfolded protein response. These strategies hold promise for treating rare mitochondrial diseases and other common disorders where mitochondrial dysfunction is a key feature, such as neurodegeneration.

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

We acknowledge funding through the MRFF Genomics Health Futures Mission - 2020 Genomics Health Futures Mission Grant Opportunity (MRF2007959) and NHMRC Ideas Grant (APP2021085) to DS.

CRedit Author Contribution

MJB: First draft writing; KQT: Figure and table; DS: Editing and final draft

Abbreviations

AFG3L2, ATPase family gene 3-like 2; ALAS1, 5-aminolevulinic acid synthase; AMPARs, AMPA receptors; BCL-2, B-cell lymphoma 2; CLPB, caseinolytic peptidase B; CLPP, caseinolytic mitochondrial matrix peptidase proteolytic subunit; CLPX, caseinolytic mitochondrial matrix peptidase chaperone subunit X; CODAS, cerebral, ocular, dental, auricular, skeletal anomalies; COX411, cytochrome c oxidase subunit 411; COXPD31, combined oxidative phosphorylation deficiency 31; EMRE, essential mitochondrial calcium uniporter regulator; EPP2, erythropoietic porphyria 2; EVPLS, epiphyseal, vertebral, ear, nose, plus associated findings; HKPX4, hyperekplexia 4; HLD4, hypomyelinating leukodystrophy 4; HSPD1, heat shock protein family D member 1; HSPE1, heat shock protein family E member 1; HSPs, heat shock proteins; HTRA2, high temperature requirement protein A2; IMM, inner mitochondrial membrane; IMS, intermembrane space; ISC, iron-sulphur cluster; LONP1, lon peptidase 1; 3-MGA-uria, 3-methylglutaconic aciduria; MGCA7A, 3-methylglutaconic aciduria 7A; MGCA7B, 3-methylglutaconic aciduria 7B; MIM, Mendelian inheritance in man; MIPEP, mitochondrial intermediate peptidase; MMDS6, multiple mitochondrial dysfunctions syndrome 6; MPP, mitochondrial processing peptidase; MT-ND1, mitochondrially encoded NADH dehydrogenase 1; MTS, mitochondrial targeting signal; NDUFB6, NADH:ubiquinone oxidoreductase subunit B6; NPHPL1, nephronophthisis-like nephropathy-1; NPHPL1, nephronophthisis-like nephropathy 1; OMA1, overlapping activity with m-AAA protease 1; OMM, outer mitochondrial membrane; OPA11, optic atrophy 11; OPA12, optic atrophy 12; OXPHOS, oxidative phosphorylation; PITRM1, pitrilysin metallopeptidase 1; PMPCA, peptidase mitochondrial processing subunit

alpha; PMPCB, peptidase mitochondrial processing subunit beta; PRLTS3, Perrault syndrome 3; PreP, presequence protease; QC, quality control; SCA28, spinocerebellar ataxia 28; SCAR2, spinocerebellar ataxia 2; SCAR30, spinocerebellar ataxia 30; SCN, severe congenital neutropenia; SCN9, severe congenital neutropenia 9; SIDBA4, sideroblastic anaemia 4; SPAX5, autosomal recessive spastic ataxia 5; SPG7, spastic paraplegia 7; SPG13, spastic paraplegia 13; TIM23, translocase of the inner membrane 23; TIMM23, translocase of inner mitochondrial membrane 23; TIMM17A, translocase of inner mitochondrial membrane 17A; TOM, translocase of the outer membrane; XIAP, X-linked inhibitor of apoptosis; XPNPEP3, x-prolyl aminopeptidase 3; YME1L1, yeast mitochondrial escape 1-like 1.

References

- 1 Anderson, A.J., Jackson, T.D., Stroud, D.A. and Stojanovski, D. (2019) Mitochondria-hubs for regulating cellular biochemistry: emerging concepts and networks. *Open Biol.* **9**, 190126 <https://doi.org/10.1098/rsob.190126> PMID: 31387448
- 2 Ng, M.Y.W., Wai, T. and Simonsen, A. (2021) Quality control of the mitochondrion. *Dev. Cell* **56**, 881–905 <https://doi.org/10.1016/j.devcel.2021.02.009> PMID: 33662258
- 3 Song, J., Herrmann, J.M. and Becker, T. (2021) Quality control of the mitochondrial proteome. *Nat. Rev. Mol. Cell Biol.* **22**, 54–70 <https://doi.org/10.1038/s41580-020-00300-2> PMID: 33093673
- 4 Baker, M.J., Cramer, J.J., Thorburn, D.R., Frazier, A.E. and Stojanovski, D. (2022) Mitochondrial biology and dysfunction in secondary mitochondrial disease. *Open Biol.* **12**, 220274 <https://doi.org/10.1098/rsob.220274> PMID: 36475414
- 5 Frazier, A.E., Thorburn, D.R. and Compton, A.G. (2019) Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology. *J. Biol. Chem.* **294**, 5386–5395 <https://doi.org/10.1074/jbc.R117.809194> PMID: 29233888
- 6 Ahrens-Nicklas, R.C., Umanah, G.K.E., Sondheimer, N., Deardorff, M.A., Wilkens, A.B., Conlin, L.K. et al. (2017) Precision therapy for a new disorder of AMPA receptor recycling due to mutations in *ATAD1*. *Neuro. Genet.* **3**, e130 <https://doi.org/10.1212/NXG.000000000000130> PMID: 28180185
- 7 Piard, J., Umanah, G.K.E., Harms, F.L., Abalde-Atristain, L., Amram, D., Chang, M. et al. (2018) A homozygous *ATAD1* mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. *Brain (Bacau)* **141**, 651–661 <https://doi.org/10.1093/brain/awx377> PMID: 29390050
- 8 Hartmann, B., Wai, T., Hu, H., MacVicar, T., Musante, L., Fischer-Zirnsak, B. et al. (2016) Homozygous *YME1L1* mutation causes mitochondrialriopathy with optic atrophy and mitochondrial network fragmentation. *Elife* **5**, e16078 <https://doi.org/10.7554/eLife.16078> PMID: 27495975
- 9 Di Bella, D., Lazzaro, F., Brusco, A., Plumari, M., Battaglia, G., Pastore, A. et al. (2010) Mutations in the mitochondrial protease gene *AFG3L2* cause dominant hereditary ataxia SCA28. *Nat. Genet.* **42**, 313–321 <https://doi.org/10.1038/ng.544> PMID: 20208537
- 10 Pierson, T.M., Adams, D., Bonn, F., Martinelli, P., Cherukuri, P.F., Teer, J.K. et al. (2011) Whole-exome sequencing identifies homozygous *AFG3L2* mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. *PLOS Genet.* **7**, e1002325 <https://doi.org/10.1371/journal.pgen.1002325> PMID: 22022284
- 11 Caporali, L., Magri, S., Legati, A., Del Dotto, V., Tagliavini, F., Balistreri, F. et al. (2020) ATPase Domain *AFG3L2* Mutations Alter OPA1 Processing and cause optic neuropathy. *Ann. Neurol.* **88**, 18–32 <https://doi.org/10.1002/ana.25723> PMID: 32219868
- 12 Atorino, L., Silvestri, L., Koppen, M., Cassina, L., Ballabio, A., Marconi, R. et al. (2003) Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. *J. Cell Biol.* **163**, 777–787 <https://doi.org/10.1083/jcb.200304112> PMID: 14623864
- 13 Casari, G., De Fusco, M., Ciarmatori, S., Zeviani, M., Mora, M., Fernandez, P. et al. (1998) Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. *Cell* **93**, 973–983 [https://doi.org/10.1016/S0092-8674\(00\)81203-9](https://doi.org/10.1016/S0092-8674(00)81203-9) PMID: 9635427
- 14 Jenkinson, E.M., Rehman, A.U., Walsh, T., Clayton-Smith, J., Lee, K., Morell, R.J. et al. (2013) Perrault syndrome is caused by recessive mutations in *CLPP*, encoding a mitochondrial ATP-dependent chambered protease. *Am. J. Hum. Genet.* **92**, 605–613 <https://doi.org/10.1016/j.ajhg.2013.02.013> PMID: 23541340
- 15 Yien, Y.Y., Ducamp, S., van der Vorm, L.N., Kardon, J.R., Manceau, H., Kannengiesser, C. et al. (2017) Mutation in human *CLPX* elevates levels of δ -aminolevulinic acid synthase and protoporphyrin IX to promote erythropoietic protoporphyria. *Proc. Natl. Acad. Sci. U.S.A.* **114**, E8045–E8052 <https://doi.org/10.1073/pnas.1700632114> PMID: 28874591
- 16 Strauss, K.A., Jinks, R.N., Puffenberger, E.G., Venkatesh, S., Singh, K., Cheng, I. et al. (2015) CODAS syndrome is associated with mutations of *LONP1*, encoding mitochondrial AAA+ Lon protease. *Am. J. Hum. Genet.* **96**, 121–135 <https://doi.org/10.1016/j.ajhg.2014.12.003> PMID: 25574826
- 17 Shebib, S.M., Reed, M.H., Shuckett, E.P., Cross, H.G., Perry, J.B. and Chudley, A.E. (1991) Newly recognized syndrome of cerebral, ocular, dental, auricular, skeletal anomalies: CODAS syndrome—a case report. *Am. J. Med. Genet.* **40**, 88–93 <https://doi.org/10.1002/ajmg.1320400118> PMID: 1887855
- 18 Brändl, B., Larson, A., Pendziwiat, M., Friederich, M.W., White, S.M. et al. (2018) Mutations in *PMPCB* encoding the catalytic subunit of the mitochondrial presequence protease cause neurodegeneration in early childhood. *Am. J. Hum. Genet.* **102**, 557–573 <https://doi.org/10.1016/j.ajhg.2018.02.014> PMID: 29576218
- 19 Jobling, R.K., Assoum, M., Gakh, O., Blaser, S., Raiman, J.A., Mignot, C. et al. (2015) *PMPCA* mutations cause abnormal mitochondrial protein processing in patients with non-progressive cerebellar ataxia. *Brain (Bacau)* **138**, 1505–1517 <https://doi.org/10.1093/brain/awv057> PMID: 25808372
- 20 Joshi, M., Anselm, I., Shi, J., Bale, T.A., Towne, M., Schmitz-Abe, K. et al. (2016) Mutations in the substrate binding glycine-rich loop of the mitochondrial processing peptidase- α protein (*PMPCA*) cause a severe mitochondrial disease. *Cold Spring Harb. Mol. Case Stud.* **2**, a000786 <https://doi.org/10.1101/mcs.a000786> PMID: 27148589

- 21 Eldomery, M.K., Akdemir, Z.C., Vögtle, F.-N., Charnig, W.-L., Mulica, P., Rosenfeld, J.A. et al. (2016) MIPEP recessive variants cause a syndrome of left ventricular non-compaction, hypotonia, and infantile death. *Genome Med.* **8**, 106 <https://doi.org/10.1186/s13073-016-0360-6> PMID: 27799064
- 22 Pulman, J., Ruzzenente, B., Horak, M., Barcia, G., Boddart, N., Munnich, A. et al. (2021) Variants in the MIPEP gene presenting with complex neurological phenotype without cardiomyopathy, impair OXPHOS protein maturation and lead to a reduced OXPHOS abundance in patient cells. *Mol. Genet. Metab.* **134**, 267–273 <https://doi.org/10.1016/j.ymgme.2021.09.005> PMID: 34620555
- 23 Alizadeh, R., Jamshidi, S., Keramatipour, M., Moeinian, P., Hosseini, R., Otukesh, H. et al. (2020) Whole exome sequencing reveals a XPNPEP3 novel mutation causing nephronophthisis in a pediatric patient. *Iran. Biomed. J.* **24**, 405–408 <https://doi.org/10.29252/ibj.24.6.400> PMID: 32660933
- 24 O'Toole, J.F., Liu, Y., Davis, E.E., Westlake, C.J., Attanasio, M., Otto, E.A. et al. (2010) Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy. *J. Clin. Invest.* **120**, 791–802, 40076 <https://doi.org/10.1172/JCI40076> PMID: 20179356
- 25 Langer, Y., Aran, A., Gulsuner, S., Abu Libdeh, B., Renbaum, P., Brunetti, D. et al. (2018) Mitochondrial *PITRM1* peptidase loss-of-function in childhood cerebellar atrophy. *J. Med. Genet.* **55**, 599–606 <https://doi.org/10.1136/jmedgenet-2018-105330> PMID: 29764912
- 26 Brunetti, D., Torsvik, J., Dallabona, C., Teixeira, P., Sztromwasser, P., Fernandez-Vizarra, E. et al. (2016) Defective PITRM1 mitochondrial peptidase is associated with A β amyloidotic neurodegeneration. *EMBO Mol. Med.* **8**, 176–190 <https://doi.org/10.15252/emmm.201505894> PMID: 26697887
- 27 Hansen, J.J., Dürr, A., Cournu-Rebeix, I., Georgopoulos, C., Ang, D., Nielsen, M.N. et al. (2002) Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. *Am. J. Hum. Genet.* **70**, 1328–1332 <https://doi.org/10.1086/339935> PMID: 11898127
- 28 Magen, D., Georgopoulos, C., Bross, P., Ang, D., Segev, Y., Goldsher, D. et al. (2008) Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. *Am. J. Hum. Genet.* **83**, 30–42 <https://doi.org/10.1016/j.ajhg.2008.05.016> PMID: 18571143
- 29 Royer-Bertrand, B., Castillo-Taucher, S., Moreno-Salinas, R., Cho, T.-J., Chae, J.-H., Choi, M. et al. (2015) Mutations in the heat-shock protein A9 (HSPA9) gene cause the EVEN-PLUS syndrome of congenital malformations and skeletal dysplasia. *Sci. Rep.* **5**, 17154 <https://doi.org/10.1038/srep17154> PMID: 26598328
- 30 Schmitz-Abe, K., Ciesielski, S.J., Schmidt, P.J., Campagna, D.R., Rahimov, F., Schilke, B.A. et al. (2015) Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. *Blood* **126**, 2734–2738 <https://doi.org/10.1182/blood-2015-09-659854> PMID: 26491070
- 31 Wortmann, S.B., Ziętkiewicz, S., Guerrero-Castillo, S., Feichtinger, R.G., Wagner, M., Russell, J. et al. (2021) Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency. *Genet. Med.* **23**, 1705–1714 <https://doi.org/10.1038/s41436-021-01194-x> PMID: 34140661
- 32 Wortmann, S.B., Ziętkiewicz, S., Kousi, M., Szklarczyk, R., Haack, T.B., Gersting, S.W. et al. (2015) CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. *Am. J. Hum. Genet.* **96**, 245–257 <https://doi.org/10.1016/j.ajhg.2014.12.013> PMID: 25597510
- 33 Warren, J.T., Cupo, R.R., Wattanasirakul, P., Spencer, D.H., Locke, A.E., Makaryan, V. et al. (2022) Heterozygous variants of CLPB are a cause of severe congenital neutropenia. *Blood* **139**, 779–791 <https://doi.org/10.1182/blood.2021010762> PMID: 34115842
- 34 Chen, Y.-C., Umanah, G.K.E., Dephoure, N., Andrabi, S.A., Gygi, S.P., Dawson, T.M. et al. (2014) Msp1/ATAD1 maintains mitochondrial function by facilitating the degradation of mislocalized tail-anchored proteins. *EMBO J.* **33**, 1548–1564 <https://doi.org/10.15252/emboj.201487943> PMID: 24843043
- 35 Kim, J., Goldstein, M., Zecchel, L., Ghorayeb, R., Maxwell, C.A. and Weidberg, H. (2024) ATAD1 prevents clogging of TOM and damage caused by un-imported mitochondrial proteins. *Cell Rep.* **43**, 114473 <https://doi.org/10.1016/j.celrep.2024.114473> PMID: 39024102
- 36 Wang, L., Toutkoushian, H., Belyy, V., Kokontis, C.Y. and Walter, P. (2022) Conserved structural elements specialize ATAD1 as a membrane protein extraction machine. *Elife* **11** <https://doi.org/10.7554/eLife.73941>
- 37 Zhang, J., Wang, Y., Chi, Z., Keuss, M.J., Pai, Y.-M.E., Kang, H.C. et al. (2011) The AAA+ ATPase Thorase Regulates AMPa receptor-dependent synaptic plasticity and behavior. *Cell* **145**, 284–299 <https://doi.org/10.1016/j.cell.2011.03.016>
- 38 Quirós, P.M., Langer, T. and López-Otín, C. (2015) New roles for mitochondrial proteases in health, ageing and disease. *Nat. Rev. Mol. Cell Biol.* **16**, 345–359 <https://doi.org/10.1038/nrm3984> PMID: 25970558
- 39 Khan, Y.A., White, K.I. and Brunger, A.T. (2022) The AAA+ superfamily: a review of the structural and mechanistic principles of these molecular machines. *Crit. Rev. Biochem. Mol. Biol.* **57**, 156–187 <https://doi.org/10.1080/10409238.2021.1979460> PMID: 34632886
- 40 Ohba, Y., MacVicar, T. and Langer, T. (2020) Regulation of mitochondrial plasticity by the i-AAA protease YME1L. *Biol. Chem.* **401**, 877–890 <https://doi.org/10.1515/hsz-2020-0120> PMID: 32087062
- 41 Patron, M., Sprenger, H.-G. and Langer, T. (2018) m-AAA proteases, mitochondrial calcium homeostasis and neurodegeneration. *Cell Res.* **28**, 296–306 <https://doi.org/10.1038/cr.2018.17> PMID: 29451229
- 42 Leonhard, K., Herrmann, J.M., Stuart, R.A., Mannhaupt, G., Neupert, W. and Langer, T. (1996) AAA proteases with catalytic sites on opposite membrane surfaces comprise a proteolytic system for the ATP-dependent degradation of inner membrane proteins in mitochondria. *EMBO J.* **15**, 4218–4229 PMID: 8861950,
- 43 Steele, T.E. and Glynn, S.E. (2019) Mitochondrial AAA proteases: A stairway to degradation. *Mitochondrion* **49**, 121–127 <https://doi.org/10.1016/j.mito.2019.07.012> PMID: 31377246
- 44 Gilkerson, R., De La Torre, P. and St Vallier, S. (2021) Mitochondrial OMA1 and OPA1 as Gatekeepers of Organellar Structure/Function and Cellular Stress Response. *Front. Cell Dev. Biol.* **9**, 626117 <https://doi.org/10.3389/fcell.2021.626117> PMID: 33842456
- 45 Hsu, M.C., Kinefuchi, H., Lei, L., Kikuchi, R., Yamano, K. and Youle, R.J. (2025) Mitochondrial YME1L1 governs unoccupied protein translocase channels. *Nat. Cell Biol.* **27**, 309–321 <https://doi.org/10.1038/s41556-024-01571-z> PMID: 39774271
- 46 Stiburek, L., Cesnekova, J., Kostkova, O., Fornuskova, D., Vinsova, K., Wenich, L. et al. (2012) YME1L controls the accumulation of respiratory chain subunits and is required for apoptotic resistance, cristae morphogenesis, and cell proliferation. *Mol. Biol. Cell* **23**, 1010–1023 <https://doi.org/10.1091/mbc.E11-08-0674> PMID: 22262461

- 47 Guzelin, E., Rep, M. and Grivell, LA. (1996) Afg3p, a mitochondrial ATP-dependent metalloprotease, is involved in degradation of mitochondrially-encoded Cox1, Cox3, Cob, Su6, Su8 and Su9 subunits of the inner membrane complexes III, IV and V. *FEBS Lett.* **381**, 42–46 [https://doi.org/10.1016/0014-5793\(96\)00074-9](https://doi.org/10.1016/0014-5793(96)00074-9) PMID: 8641436
- 48 Arlt, H., Steglich, G., Perryman, R., Guiard, B., Neupert, W. and Langer, T. (1998) The formation of respiratory chain complexes in mitochondria is under the proteolytic control of the m-AAA protease. *EMBO J.* **17**, 4837–4847 <https://doi.org/10.1093/emboj/17.16.4837> PMID: 9707443
- 49 Cesnekova, J., Rodinova, M., Hansikova, H., Zeman, J. and Stiburek, L. (2018) Loss of Mitochondrial AAA Proteases AFG3L2 and YME1L Impairs Mitochondrial Structure and Respiratory Chain Biogenesis **19** <https://doi.org/10.3390/ijms19123930>
- 50 Consolato, F., Maltecca, F., Tulli, S., Sambri, I. and Casari, G. (2018) m-AAA and i-AAA complexes coordinate to regulate OMA1, the stress-activated supervisor of mitochondrial dynamics. *J. Cell. Sci.* **131**, jcs213546 <https://doi.org/10.1242/jcs.213546> PMID: 29545505
- 51 Ehses, S., Raschke, I., Mancuso, G., Bernacchia, A., Geimer, S., Tondera, D. et al. (2009) Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. *J. Cell Biol.* **187**, 1023–1036 <https://doi.org/10.1083/jcb.200906084> PMID: 20038678
- 52 Maltecca, F., Baseggio, E., Consolato, F., Mazza, D., Podini, P., Young, S.M., Jr et al. (2015) Purkinje neuron Ca²⁺ influx reduction rescues ataxia in SCA28 model. *J. Clin. Invest.* **125**, 263–274, 74770 <https://doi.org/10.1172/JCI74770> PMID: 25485680
- 53 König, T., Tröder, S.E., Bakka, K., Korwitz, A., Richter-Dennerlein, R., Lampe, P.A. et al. (2016) The m-AAA Protease Associated with Neurodegeneration Limits MCU Activity in Mitochondria. *Mol. Cell* **64**, 148–162 <https://doi.org/10.1016/j.molcel.2016.08.020> PMID: 27642048
- 54 Yu-Wai-Man, P., Griffiths, P.G., Burke, A., Sellar, P.W., Clarke, M.P., Gnanaraj, L. et al. (2010) The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. *Ophthalmology* **117**, 1538–1546, 46.e1 <https://doi.org/10.1016/j.ophtha.2009.12.038> PMID: 20417570
- 55 Cartoni, R. and Martinou, J.-C. (2009) Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A. *Exp. Neurol.* **218**, 268–273 <https://doi.org/10.1016/j.expneurol.2009.05.003> PMID: 19427854
- 56 Szczepanowska, K. and Trifunovic, A. (2022) Mitochondrial matrix proteases: quality control and beyond. *FEBS J.* **289**, 7128–7146 <https://doi.org/10.1111/febs.15964> PMID: 33971087
- 57 Kang, S.G., Dimitrova, M.N., Ortega, J., Ginsburg, A. and Maurizi, MR. (2005) Human mitochondrial ClpP is a stable heptamer that assembles into a tetradecamer in the presence of ClpX. *J. Biol. Chem.* **280**, 35424–35432 <https://doi.org/10.1074/jbc.M507240200> PMID: 16115876
- 58 Kang, S.G., Ortega, J., Singh, S.K., Wang, N., Huang, N.-N., Steven, A.C. et al. (2002) Functional proteolytic complexes of the human mitochondrial ATP-dependent protease, hClpXP. *J. Biol. Chem.* **277**, 21095–21102 <https://doi.org/10.1074/jbc.M201642200> PMID: 11923310
- 59 Kerešič, S., Kováčik, L., Bednár, J., Pevala, V., Kunová, N., Ondrovičová, G. et al. (2016) The N-terminal domain plays a crucial role in the structure of a full-length human mitochondrial Lon protease. *Sci. Rep.* **6**, 33631 <https://doi.org/10.1038/srep33631> PMID: 27632940
- 60 Shin, M., Watson, E.R., Song, A.S., Mindrebo, J.T., Novick, S.J., Griffin, P.R. et al. (2021) Structures of the human LONP1 protease reveal regulatory steps involved in protease activation. *Nat. Commun.* **12**, 3239 <https://doi.org/10.1038/s41467-021-23495-0> PMID: 34050165
- 61 Mindrebo, J.T. and Lander, G.C. (2024) Structural and mechanistic studies on human LONP1 redefine the hand-over-hand translocation mechanism. *bioRxiv* 2024.06.24.600538 <https://doi.org/10.1101/2024.06.24.600538> PMID: 38979310
- 62 Szczepanowska, K., Maiti, P., Kukat, A., Hofsetz, E., Nolte, H., Senft, K. et al. (2016) CLPP coordinates mitoribosomal assembly through the regulation of ERAL1 levels. *EMBO J.* **35**, 2566–2583 <https://doi.org/10.15252/embj.201694253> PMID: 27797820
- 63 Szczepanowska, K., Senft, K., Heidler, J., Herholz, M., Kukat, A., Höhne, M.N. et al. (2020) A salvage pathway maintains highly functional respiratory complex I. *Nat. Commun.* **11**, 1643 <https://doi.org/10.1038/s41467-020-15467-7> PMID: 32242014
- 64 Kardon, J.R., Yien, Y.Y., Huston, N.C., Branco, D.S., Hildick-Smith, G.J., Rhee, K.Y. et al. (2015) Mitochondrial ClpX Activates a Key enzyme for heme biosynthesis and erythropoiesis. *Cell* **161**, 858–867 <https://doi.org/10.1016/j.cell.2015.04.017>
- 65 Quirós, P.M., Español, Y., Acín-Pérez, R., Rodríguez, F., Bárcena, C., Watanabe, K. et al. (2014) ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. *Cell Rep* **8**, 542–556 <https://doi.org/10.1016/j.celrep.2014.06.018> PMID: 25017063
- 66 Gibellini, L., Pinti, M., Boraldi, F., Giorgio, V., Bernardi, P., Bartolomeo, R. et al. (2014) Silencing of mitochondrial Lon protease deeply impairs mitochondrial proteome and function in colon cancer cells. *FASEB J.* **28**, 5122–5135 <https://doi.org/10.1096/fj.14-255869> PMID: 25154874
- 67 Bota, D.A., Ngo, J.K. and Davies, KJA. (2005) Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death. *Free Radic. Biol. Med.* **38**, 665–677 <https://doi.org/10.1016/j.freeradbiomed.2004.11.017> PMID: 15683722
- 68 De Gaetano, A., Mandrioli, M., Van Tongeren, E., Bortolotti, C.A., Cossarizza, A. et al. (2020) The biology of Lonp1: more than a mitochondrial protease. *Int. Rev. Cell Mol. Biol.* **354**, 1–61 <https://doi.org/10.1016/bs.ircmb.2020.02.005> PMID: 32475470
- 69 Matsushima, Y., Takahashi, K., Yue, S., Fujiyoshi, Y., Yoshioka, H., Aihara, M. et al. (2021) Mitochondrial Lon protease is a gatekeeper for proteins newly imported into the matrix. *Commun. Biol.* **4**, 974 <https://doi.org/10.1038/s42003-021-02498-z> PMID: 34400774
- 70 Pollecker, K., Sylvestre, M. and Voos, W. (2021) Proteomic analysis demonstrates the role of the quality control protease LONP1 in mitochondrial protein aggregation. *J. Biol. Chem.* **297**, 101134 <https://doi.org/10.1016/j.jbc.2021.101134> PMID: 34461102
- 71 Zurita Rendón, O. and Shoubridge, EA. (2018) LONP1 Is Required for Maturation of a Subset of Mitochondrial Proteins, and Its Loss Elicits an Integrated Stress Response. *Mol. Cell. Biol.* **38**, e00412-17 <https://doi.org/10.1128/MCB.00412-17> PMID: 30061372
- 72 Deshwal, S., Fiedler, K.U. and Langer, T. (2020) Mitochondrial proteases: multifaceted regulators of mitochondrial plasticity. *Annu. Rev. Biochem.* **89**, 501–528 <https://doi.org/10.1146/annurev-biochem-062917-012739> PMID: 32075415
- 73 Botham, A., Coyaud, E., Nirmalanandhan, V.S., Gronda, M., Hurren, R., Maclean, N. et al. (2019) Global interactome mapping of mitochondrial intermembrane space proteases identifies a novel function for HTRA2. *Proteomics* **19**, e1900139 <https://doi.org/10.1002/pmic.201900139> PMID: 31617661
- 74 Kieper, N., Holmström, K.M., Ciceri, D., Fiesel, F.C., Wolburg, H., Ziviani, E. et al. (2010) Modulation of mitochondrial function and morphology by interaction of Omi/HtrA2 with the mitochondrial fusion factor OPA1. *Exp. Cell Res.* **316**, 1213–1224 <https://doi.org/10.1016/j.yexcr.2010.01.005> PMID: 20064504

- 75 Martins, L.M., Iaccarino, I., Tenev, T., Gschmeissner, S., Totty, N.F., Lemoine, N.R. et al. (2002) The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. *J. Biol. Chem.* **277**, 439–444 <https://doi.org/10.1074/jbc.M109784200> PMID: 11602612
- 76 Hegde, R., Srinivasula, S.M., Zhang, Z., Wassell, R., Mukattash, R., Cilenti, L. et al. (2002) Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. *J. Biol. Chem.* **277**, 432–438 <https://doi.org/10.1074/jbc.M109721200> PMID: 11606597
- 77 Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K. and Takahashi, R. (2001) A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. *Mol. Cell* **8**, 613–621 [https://doi.org/10.1016/s1097-2765\(01\)00341-0](https://doi.org/10.1016/s1097-2765(01)00341-0) PMID: 11583623
- 78 Verhagen, A.M., Ekert, P.G., Pakusch, M., Silke, J., Connolly, L.M., Reid, G.E. et al. (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* **102**, 43–53 [https://doi.org/10.1016/s0092-8674\(00\)00009-x](https://doi.org/10.1016/s0092-8674(00)00009-x) PMID: 10929712
- 79 Toyama, Y., Harkness, R.W., Lee, T.Y.T., Maynes, J.T. and Kay, L.E. (2021) Oligomeric assembly regulating mitochondrial HtrA2 function as examined by methyl-TROSY NMR. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2025022118 <https://doi.org/10.1073/pnas.2025022118> PMID: 33692127
- 80 Aspholm, E.E., Lidman, J. and Burmann, B.M. (2024) Structural basis of substrate recognition and allosteric activation of the proapoptotic mitochondrial HtrA2 protease. *Nat. Commun.* **15**, 4592 <https://doi.org/10.1038/s41467-024-48997-5> PMID: 38816423
- 81 Mandel, H., Saita, S., Edvardson, S., Jalas, C., Shaag, A., Goldsher, D. et al. (2016) Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria. *J. Med. Genet.* **53**, 690–696 <https://doi.org/10.1136/jmedgenet-2016-103922> PMID: 27208207
- 82 Oláhová, M., Thompson, K., Hardy, S.A., Barbosa, I.A., Besse, A., Anagnostou, M.-E. et al. (2017) Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria. *J. Inher. Metab. Dis.* **40**, 121–130 <https://doi.org/10.1007/s10545-016-9977-2> PMID: 27696117
- 83 Kovacs-Nagy, R., Morin, G., Nouri, M.A., Brandau, O., Saadi, N.W., Nouri, M.A. et al. (2018) HTRA2 Defect: a recognizable inborn error of metabolism with 3-methylglutaconic aciduria as discriminating feature characterized by neonatal movement disorder and epilepsy-report of 11 patients. *Neuropediatrics* **49**, 373–378 <https://doi.org/10.1055/s-0038-1667345> PMID: 30114719
- 84 Sreedhara, M.S., Balakrishnan, U., Amboiram, P., Chandrasekeran, A., Abiramalatha, T., Mohammad, S.J.S. et al. (2020) 3-Methylglutaconic aciduria type VIII in an Indian neonate. *Birth Defects Res.* **112**, 1093–1097 <https://doi.org/10.1002/bdr2.1717> PMID: 32445293
- 85 Gurusamy, U., Ramadesikan, S., Marhabaie, M., Colwell, C.M., Hunter, J.M., Leung, M.L. et al. (2023) Biallelic variants in HTRA2 cause 3-methylglutaconic aciduria mitochondrial disorder: case report and literature review. *Front. Genet.* **14**, 1298574 <https://doi.org/10.3389/fgene.2023.1298574> PMID: 38304066
- 86 Abe, Y., Shodai, T., Muto, T., Mihara, K., Torii, H., Nishikawa, S. et al. (2000) Structural basis of presequence recognition by the mitochondrial protein import receptor Tom20. *Cell* **100**, 551–560 [https://doi.org/10.1016/s0092-8674\(00\)80691-1](https://doi.org/10.1016/s0092-8674(00)80691-1) PMID: 10721992
- 87 Vögtle, F.-N., Wortelkamp, S., Zahedi, R.P., Becker, D., Leidhold, C., Gevaert, K. et al. (2009) Global analysis of the mitochondrial N-proteome identifies a processing peptidase critical for protein stability. *Cell* **139**, 428–439 <https://doi.org/10.1016/j.cell.2009.07.045> PMID: 19837041
- 88 Callegari, S., Cruz-Zaragoza, L.D. and Rehling, P. (2020) From TOM to the TIM23 complex - handing over of a precursor. *Biol. Chem.* **401**, 709–721 <https://doi.org/10.1515/hsz-2020-0101> PMID: 32074073
- 89 Kang, Y., Fielden, L.F. and Stojanovski, D. (2018) Mitochondrial protein transport in health and disease. *Semin. Cell Dev. Biol.* **76**, 142–153 <https://doi.org/10.1016/j.semcdb.2017.07.028>
- 90 Hendrick, J.P., Hodges, P.E. and Rosenberg, L.E. (1989) Survey of amino-terminal proteolytic cleavage sites in mitochondrial precursor proteins: leader peptides cleaved by two matrix proteases share a three-amino acid motif. *Proc. Natl. Acad. Sci. U.S.A.* **86**, 4056–4060 <https://doi.org/10.1073/pnas.86.11.4056> PMID: 2657736
- 91 Branda, S.S. and Isaya, G. (1995) Prediction and identification of new natural substrates of the yeast mitochondrial intermediate peptidase. *J. Biol. Chem.* **270**, 27366–27373 <https://doi.org/10.1074/jbc.270.45.27366> PMID: 7593000
- 92 Singh, R., Jamdar, S.N., Goyal, V.D., Kumar, A., Ghosh, B. and Makde, R.D. (2017) Structure of the human aminopeptidase XPNPEP3 and comparison of its *in vitro* activity with Icp55 orthologs: Insights into diverse cellular processes. *J. Biol. Chem.* **292**, 10035–10047 <https://doi.org/10.1074/jbc.M117.783357> PMID: 28476889
- 93 Hoff, S., Halbritter, J., Epting, D., Frank, V., Nguyen, T.-M.T., Van Reeuwijk, J. et al. (2013) ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. *Nat. Genet.* **45**, 951–956 <https://doi.org/10.1038/ng.2681> PMID: 23793029
- 94 Stahl, A., Moberg, P., Ytterberg, J., Panfilov, O., Brockenhuus Von Lowenhielm, H., Nilsson, F. et al. (2002) Isolation and identification of a novel mitochondrial metalloprotease (PreP) that degrades targeting presequences in plants. *J. Biol. Chem.* **277**, 41931–41939 <https://doi.org/10.1074/jbc.M205500200> PMID: 12138166
- 95 Chow, K.M., Gakh, O., Payne, I.C., Juliano, M.A., Juliano, L., Isaya, G. et al. (2009) Mammalian pitrilysin: substrate specificity and mitochondrial targeting. *Biochemistry* **48**, 2868–2877 <https://doi.org/10.1021/bi8016125> PMID: 19196155
- 96 Kücükköse, C., Taskin, A.A., Marada, A., Brummer, T., Dennerlein, S. and Vögtle, F.N. (2021) Functional coupling of presequence processing and degradation in human mitochondria. *FEBS J.* **288**, 600–613 <https://doi.org/10.1111/febs.15358> PMID: 32491259
- 97 Pérez, M.J., Ivanyuk, D., Panagiotakopoulou, V., Di Napoli, G., Kalb, S., Brunetti, D. et al. (2021) Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids. *Mol. Psychiatry* **26**, 5733–5750 <https://doi.org/10.1038/s41380-020-0807-4> PMID: 32632204
- 98 Ashleigh, T., Swerdlow, R.H. and Beal, M.F. (2023) The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. *Alzheimers. Dement.* **19**, 333–342 <https://doi.org/10.1002/alz.12683>
- 99 Wang, W., Zhao, F., Ma, X., Perry, G. and Zhu, X. (2020) Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. *Mol. Neurodegener.* **15**, 30 <https://doi.org/10.1186/s13024-020-00376-6> PMID: 32471464
- 100 Kampinga, H.H., Hageman, J., Vos, M.J., Kubota, H., Tanguay, R.M., Bruford, E.A. et al. (2009) Guidelines for the nomenclature of the human heat shock proteins. *Cell Stress Chaperones* **14**, 105–111 <https://doi.org/10.1007/s12192-008-0068-7> PMID: 18663603

- 101 Young, J.C., Hoogenraad, N.J. and Hartl, F.U. (2003) Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. *Cell* **112**, 41–50 [https://doi.org/10.1016/s0092-8674\(02\)01250-3](https://doi.org/10.1016/s0092-8674(02)01250-3) PMID: 12526792
- 102 Becker, T., Song, J. and Pfanner, N. (2019) Versatility of Preprotein Transfer from the Cytosol to Mitochondria. *Trends Cell Biol* **29**, 534–548 <https://doi.org/10.1016/j.tcb.2019.03.007> PMID: 31030976
- 103 Adriaenssens, E., Asselbergh, B., Rivera-Mejías, P., Bervoets, S., Vendredy, L., De Winter, V. et al. (2023) Small heat shock proteins operate as molecular chaperones in the mitochondrial intermembrane space. *Nat. Cell Biol.* **25**, 467–480 <https://doi.org/10.1038/s41556-022-01074-9> PMID: 36690850
- 104 Bahr, T., Katuri, J., Liang, T. and Bai, Y. (2022) Mitochondrial chaperones in human health and disease. *Free Radical Biology and Medicine* **179**, 363–374 <https://doi.org/10.1016/j.freeradbiomed.2021.11.015>
- 105 Singh, M.K., Shin, Y., Han, S., Ha, J., Tiwari, P.K., Kim, S.S. et al. (2024) Molecular chaperonin HSP60: current understanding and future prospects. *Int. J. Mol. Sci.* **25**, 5483 <https://doi.org/10.3390/ijms25105483> PMID: 38791521
- 106 Gomez-Llorente, Y., Jebara, F., Patra, M., Malik, R., Nisemblat, S., Chomsky-Hecht, O. et al. (2020) Structural basis for active single and double ring complexes in human mitochondrial Hsp60-Hsp10 chaperonin. *Nat. Commun.* **11**, 1916 <https://doi.org/10.1038/s41467-020-15698-8> PMID: 32317635
- 107 Klebl, D.P., Feasey, M.C., Hesketh, E.L., Ranson, N.A., Wurdak, H., Sobott, F. et al. (2021) Cryo-EM structure of human mitochondrial HSPD1. *iScience* **24**, 102022 <https://doi.org/10.1016/j.isci.2020.102022> PMID: 33506187
- 108 Bie, A.S., Cömert, C., Körner, R., Corydon, T.J., Palmfeldt, J., Hipp, M.S. et al. (2020) An inventory of interactors of the human HSP60/HSP10 chaperonin in the mitochondrial matrix space. *Cell Stress and Chaperones* **25**, 407–416 <https://doi.org/10.1007/s12192-020-01080-6>
- 109 Christensen, J.H., Nielsen, M.N., Hansen, J., Füchtbauer, A., Füchtbauer, E.-M., West, M. et al. (2010) Inactivation of the hereditary spastic paraplegia-associated Hspd1 gene encoding the Hsp60 chaperone results in early embryonic lethality in mice. *Cell Stress and Chaperones* **15**, 851–863 <https://doi.org/10.1007/s12192-010-0194-x>
- 110 Cömert, C., Kjær-Sørensen, K., Hansen, J., Carlsen, J., Just, J., Meaney, B.F. et al. (2024) HSP60 chaperone deficiency disrupts the mitochondrial matrix proteome and dysregulates cholesterol synthesis. *Mol. Metab.* **88**, 102009 <https://doi.org/10.1016/j.molmet.2024.102009> PMID: 39147275
- 111 Fontaine, B., Davoine, C.S., Dürr, A., Paternotte, C., Feki, I., Weissenbach, J. et al. (2000) A new locus for autosomal dominant pure spastic paraplegia, on chromosome 2q24–q34. *Am. J. Hum. Genet.* **66**, 702–707 <https://doi.org/10.1086/302776> PMID: 10677329
- 112 Shin, C.-S., Meng, S., Garbis, S.D., Moradian, A., Taylor, R.W., Sweredoski, M.J. et al. (2021) LONP1 and mtHSP70 cooperate to promote mitochondrial protein folding. *Nat. Commun.* **12**, 265 <https://doi.org/10.1038/s41467-020-20597-z> PMID: 33431889
- 113 Alfadhel, M., Nashabat, M., Abu Ali, Q. and Hundallah, K. (2017) Mitochondrial iron-sulfur cluster biogenesis from molecular understanding to clinical disease. *Neurosciences (Riyadh)*. **22**, 4–13 <https://doi.org/10.17712/nsj.2017.1.20160542> PMID: 28064324
- 114 Rouault, T.A. and Maio, N. (2017) Biogenesis and functions of mammalian iron-sulfur proteins in the regulation of iron homeostasis and pivotal metabolic pathways. *J. Biol. Chem* **292**, 12744–12753 <https://doi.org/10.1074/jbc.R117.789537> PMID: 28615439
- 115 Shan, Y. and Cortopassi, G. (2016) Mitochondrial Hspa9/Mortalin regulates erythroid differentiation via iron-sulfur cluster assembly. *Mitochondrion* **26**, 94–103 <https://doi.org/10.1016/j.mito.2015.12.005> PMID: 26702583
- 116 Nillegoda, N.B., Wentink, A.S. and Bukau, B. (2018) Protein disaggregation in multicellular organisms. *Trends Biochem. Sci* **43**, 285–300 <https://doi.org/10.1016/j.tibs.2018.02.003> PMID: 29501325
- 117 Wu, D., Liu, Y., Dai, Y., Wang, G., Lu, G., Chen, Y. et al. (2023) Comprehensive structural characterization of the human AAA+ disaggregase CLPB in the apo- and substrate-bound states reveals a unique mode of action driven by oligomerization. *PLoS Biol.* **21**, e3001987 <https://doi.org/10.1371/journal.pbio.3001987> PMID: 36745679
- 118 Cupo, R.R., Rizo, A.N., Braun, G.A., Tse, E., Chuang, E., Gupta, K. et al. (2022) Unique structural features govern the activity of a human mitochondrial AAA+ disaggregase, Skd3. *Cell Rep* **40**, 111408 <https://doi.org/10.1016/j.celrep.2022.111408> PMID: 36170828
- 119 Cupo, R.R. and Shorter, J. (2020) Skd3 (human ClpB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations. *Elife* **9**, e55279 <https://doi.org/10.7554/eLife.55279> PMID: 32573439
- 120 Baker, M.J., Blau, K.U., Anderson, A.J., Palmer, C.S., Fielden, L.F., Cramer, J.J. et al. (2024) CLPB disaggregase dysfunction impacts the functional integrity of the proteolytic SPY complex. *J. Cell Biol.* **223**, e202305087 <https://doi.org/10.1083/jcb.202305087> PMID: 38270563
- 121 Yoshinaka, T., Kosako, H., Yoshizumi, T., Furukawa, R., Hirano, Y., Kuge, O. et al. (2019) Structural basis of mitochondrial scaffolds by prohibitin complexes: insight into a role of the coiled-coil region. *iScience* **19**, 1065–1078 <https://doi.org/10.1016/j.isci.2019.08.056>
- 122 Chen, X., Glytsou, C., Zhou, H., Narang, S., Reyna, D.E., Lopez, A. et al. (2019) Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. *Cancer Discov.* **9**, 890–909 <https://doi.org/10.1158/2159-8290.CD-19-0117> PMID: 31048321